Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

usiness Officer.  Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business Development and Global Marketing groups.  He will also oversee InterMune's Canadian business and the company's manufacturing and supply chain operations. 
  • On February 19, InterMune reported that the company and Shionogi & Co., Ltd had reached an agreement regarding the material terms of a settlement of the complaint filed by Shionogi against InterMune.  Effective January 1, 2013, InterMune agrees to pay Shionogi a royalty of 4.25% on net sales of Esbriet in the European Union through the remaining period of Orphan Drug exclusivity ending in February 2021.  Shionogi waives any claim against InterMune to royalties on European sales of Esbriet prior to January 1, 2013 and any claim to royalties on Esbriet sales in Canada or in the United States.  The previous agreement provided for a royalty structure on net sales of pirfenidone equal to 6% of net sales for the first and second calendar year following commercialization, 8% of net sales for the third and fourth calendar year following commercialization and 10% of net sales for each subsequent calendar year thereafter.
  • Fourth Quarter and Full Year 2012 Financial Results (Unaudited)
    InterMune reported total revenue in the fourth quarter of 2012 of $8.2 million, compared with $2.7 million in the fourth quarter of 2011, an increase of 204 percent.  Fourth quarter 2012 results included the effect of the approximate 11 percent German price decrease of Esbriet, which became effective on September 15, 2012.  InterMune reported total revenue for the full year 2012 of $26.2 million, compared with $5.4 million in 2011, an increase of 385 percent.  Total revenue in 2011 consisted of $2.8 million of Esbriet revenue and $2.6 million of revenue from the company's research collaboration with Roche, which was completed in June 2011.Research and development (R
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
    (Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
    (Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
    (Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
    ... May 7 The Sixth Annual Healthcare Unbound Conference ... (TCBI), will feature the coming together of consumer and ... The Conference will take place at the ... 2009. Attendees will include a diverse representation of ...
    ... May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., ... technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP(TM)) System ... that Eric D. Whitman, MD, Director of the Atlantic Melanoma ... will present at The 7th World Congress on Melanoma, to ...
    ... Parma Group has reacquired the,marketing rights to its own ... of the American pharmaceutical company Cornerstone; it will,be setting ... market. This presence in the USA will prepare the ... of respiratory illnesses. , The ...
    Cached Biology Technology:Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 2Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 3The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3
    (Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
    (Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
    (Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
    Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
    ... eggs in the nest of a magpie so that their ... their young are not raised together with other magpies. The ... by their foster parents are much lower, according to research ... Spain. The findings are published in Springer,s journal Behavioral ...
    ... time, large-scale information on the biochemical makeup of ... These molecules are used in research to help ... Making these data accessible to researchers worldwide increases ... NIH,s National Center for Advancing Translational ...
    ... Calif. , Dec. 11, 2013  DigitalPersona, Inc., ... today announced that the DigitalPersona ® FingerJet ... certified by the National Institute of Standards and ... program to meet the United States Government,s  Personal ...
    Cached Biology News:Magpie parents know a baby cuckoo when they see one 2Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2
    GLP-1 (HYB 147-12)...
    ... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
    EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
    Kit containing positive control DNA all parts of the HIV-1 genome, HIV-1 negative control DNA, Primers SK38, SK39, SK19...
    Biology Products: